Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
|Articles|September 1, 2003
Mysterious Scarring Alopecias
Author(s)Coriene E. Hannapel
Chicago - Current focus on the scarring alopecias (cicatricial alopecias), one of the most poorly understood disorders in dermatology for which no effective therapies exist, is to generate research that will lead first to an understanding of these disorders and then to development of effective treatments, according to Wilma F. Bergfeld, M.D. Efforts are being made to update and clarify the current gold standard of the diagnosis, both clinical and histological, as well as the present therapies.
Advertisement
Advertisement
Related to this article
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
4
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
5